Role of Nicorandil effect on Contrast Induced Nephropathy in patients land for elective PCI

Background: Patients having percutaneous coronary intervention (PCI) and coronary angiography (CAG) are more likely to experience contrast-induced nephropathy (CIN), which is linked to higher mortality and morbidity (PCI). Our goal was to assess the effectiveness of nicorandil medication given to patients getting ready for elective PCI in reducing the occurrence of CIN. Methods: 400 eligible patients in total were included in the trial and divided into the control (n = 200) and nicorandil (n = 200) groups. Patients in the nicorandil group were given 10 mg of nicorandil twice (oral) beginning one week before and continuing orally with the same dose for two days after an elective PCI in addition to the conventional hydration therapy. Serum creatinine (SCr) levels were assessed 24 hours prior to and 48 hours following the procedure. Results: The mean baseline creatinine level among patients in Nicorandil group was 1.064±0.34 and that for patients in control group was 1.11±0.31 (P-value=0.150). After the procedure, the mean creatinine level was 1.097±0.34 in Nicorandil group and 1.25±0.52 in control group with statistically significant difference (P-value=0.003). There was a significant higher creatinine level after the procedure in both groups but, the increase was more in the control group than Nicorandil group. In control group, the serum creatinine increased from 1.111±0.31 to 1.25±0.52 while in Nicorandil group increased from 1.064±0.34 to 1.097±0.34 (P-value Conclusions: In individuals receiving an elective cardiac intervention, Nicorandil may have a protective effect against CIN and lessen adverse outcomes.